Results 151 to 160 of about 126,590 (205)
Some of the next articles are maybe not open access.
Journal of Pediatric Health Care, 1999
Hepatitis B virus (HBV) infection is a health problem that affects numerous infants and children in the United States. Approximately 4000 to 6000 new infections occur each year in children and adolescents; most often they become infected without obvious clinical manifestations. Some persons become chronically infected, and this asymptomatic chronically
M J, Ott, M, Aruda
openaire +2 more sources
Hepatitis B virus (HBV) infection is a health problem that affects numerous infants and children in the United States. Approximately 4000 to 6000 new infections occur each year in children and adolescents; most often they become infected without obvious clinical manifestations. Some persons become chronically infected, and this asymptomatic chronically
M J, Ott, M, Aruda
openaire +2 more sources
The Lancet, 1976
The high rate of infection with hepatitis B virus in certain defined populations in industralized countries and among the general population in many non-industrialized countries stresses the need for hepatitis B vaccines. Hepatitis B, one of at least six different forms of viral hepatitis, may progress to chronic liver disease, including chronic ...
openaire +2 more sources
The high rate of infection with hepatitis B virus in certain defined populations in industralized countries and among the general population in many non-industrialized countries stresses the need for hepatitis B vaccines. Hepatitis B, one of at least six different forms of viral hepatitis, may progress to chronic liver disease, including chronic ...
openaire +2 more sources
Vaccine, 2003
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +3 more sources
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +3 more sources
Hepatitis B Vaccination Safety
Annals of Pharmacotherapy, 2002BACKGROUND: Recent studies have suggested that adult hepatitis B vaccination may be associated with adverse reactions. OBJECTIVE: To further examine the relative risk, percentage association, and statistical significance of arthritic, immunologic, and gastrointestinal adverse reactions reported after adult hepatitis B vaccination compared with control ...
Mark R, Geier, David A, Geier
openaire +2 more sources
Journal of Virological Methods, 1985
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +2 more sources
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +2 more sources
Journal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +2 more sources
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +2 more sources
Vaccine, 1983
Abstract Hepatitis B is endemic in many African, Asian and Pacific countries causing much debilitation and death. The disease can lead to chronic cirrhosis and is closely associated with liver cell cancer. There are in the order of 200 million people that carry the virus and constitute a huge reservoir of infection.
openaire +2 more sources
Abstract Hepatitis B is endemic in many African, Asian and Pacific countries causing much debilitation and death. The disease can lead to chronic cirrhosis and is closely associated with liver cell cancer. There are in the order of 200 million people that carry the virus and constitute a huge reservoir of infection.
openaire +2 more sources
Intradermal Hepatitis B Vaccination
DICP, 1991The availability of vaccine since 1982 for immunization against hepatitis B virus (HBV) has had minimal impact on the disease; mass immunization has been suggested. Intradermal vaccination, which has precedent in prophylaxis of other infectious diseases, has been investigated as a low-cost alternative to traditional intramuscular HBV vaccination ...
M P, Rivey, J, Peterson
openaire +2 more sources
Vaccine, 1998
Currently available hepatitis B vaccines are immunogenic, efficacious and safe. There is no doubt that their consistent use makes the elimination of hepatitis B in most countries possible. Nevertheless, there are still aspects of these vaccines which could be improved: three doses are needed for a full course of vaccination (which is sometimes ...
openaire +2 more sources
Currently available hepatitis B vaccines are immunogenic, efficacious and safe. There is no doubt that their consistent use makes the elimination of hepatitis B in most countries possible. Nevertheless, there are still aspects of these vaccines which could be improved: three doses are needed for a full course of vaccination (which is sometimes ...
openaire +2 more sources
Combination Hepatitis A-Hepatitis B Vaccine
BioDrugs, 1997The adult formulation of this combination hepatitis A-hepatitis B vaccine contains 720 enzyme-linked immunosorbent assay units (EU) of formalin-inactivated hepatitis A virus strain HM175 and 20mug of recombinant DNA yeast-derived hepatitis B surface antigen adsorbed onto aluminium salts in 1ml for injection.
A J, Wagstaff, J A, Balfour
openaire +2 more sources